Trends in Patient Access: How Health Reform, Cost of Care and Stakeholder Response Will Shape Pharmaceutical Product Utilization
Questions abound over the impact that health reform and related measures will have on patients’ ability to receive the medications they want and need.
 Bob Mauch
President
Xcenda
Interviewer: Bill Looney | Join us as we discuss what pharmaceutical manufacturers, payers, providers and patients are doing in response to this dynamic healthcare environment. Pharmaceutical Executive Editor-in-Chief Bill Looney visits with Bob Mauch, president of Xcenda, to discuss:
- How health reform might affect quality of care and what preparations are being made by stakeholders like manufacturers and payers
- Immediate and potential long-term impact of biosimilars in the specialty space
- Use of patient adherence and patient assistance programs as a way to promote proper therapy utilization
- The current and future state of hot button issues like comparative effectiveness and REMS
| 
Add this Podcast feed to your media player
Click Here To Listen to More of the ABSG Podcast Series
|
Sponsored By  |
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA